ArticleAnnals of surgical oncology2025
The Effectiveness of Superparamagnetic Iron Oxide Nanoparticles in Reducing Unnecessary Sentinel Lymph Node Biopsies.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nanoplatforms for Sentinel and Tumor-Draining Lymph Node Mapping: From Visualization to Pathway-Informed Staging.Advanced healthcare materials · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSentinel lymph node biopsy (SLNB) is routinely performed at the time of mastectomy for noninvasive breast disease owing to the potential upgrade on final pathology, resulting in 80% of patients receiving unnecessary SLNB. Superparamagnetic iron oxide nanoparticles (SPIO) are a tracer with extended lymph node marking, facilitating delayed node retrieval in the event of an invasive upgrade. This study assesses the utilization and efficacy of SPIO for potential delayed SLNB for patients undergoing mastectomy. PATIENTS AND
methodsA retrospective cohort study identified SPIO use from September 2019 to August 2023. Two-sample t-tests, chi squared, and ANOVA were performed to compare indication, clinicopathology, and surgery details among those with or without SPIO injection in patients undergoing mastectomy for ductal carcinoma in situ (DCIS).
resultsA total of 77 patients received SPIO injection: 33 (42.9%) for potential delayed SLNB and 44 (57.1%) for same-day SLNB. Indications for SPIO use for delaying SLNB were DCIS (23; 69.7%), abnormal imaging (5; 15.2%), high-risk lesions (3; 9.1%), and breast cancer gene (BRCA) mutation (2; 6.1%). A total of 9 out of 33 (27.3%) patients experienced an upgrade and underwent SLNB at a mean of 20 days (range 11-27) after mastectomy, with no differences in the number of nodes removed (2 versus 2.51 nodes; p = 0.61). Of patients undergoing mastectomy for DCIS, 23 (29.5%) received SPIO, while 54 (70.1%) underwent immediate SLNB. Deep inferior epigastric perforator flap reconstruction (p = 0.0021) and necrosis on core needle biopsy (p = 0.00014) were associated with immediate SLNB.
conclusionsWhen utilized at the time of mastectomy for noninvasive disease, most patients receiving SPIO were spared unnecessary axillary surgery and the associated morbidities.
Indexed as
Identifiers
40080369What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.